biote Corp. SEC Filings

biote Corp. reported weaker results for the three months ended June 30, 2026. Total revenue was $44,232 thousand, down from $48,863 thousand a year earlier, as pellet procedure revenue declined while dietary supplement revenue grew modestly. Selling, general and administrative expense rose to $32,426 thousand from $24,223 thousand, including $5,100 thousand of charges tied to legal settlements and other resolved matters. Income from operations swung to a loss of $3,508 thousand compared with income of $10,765 thousand in 2025. Net loss attributable to stockholders was $6,563 thousand versus net income of $3,185 thousand, or basic and diluted loss per share of $0.23.

For the six months ended June 30, 2026, revenue was $89,167 thousand versus $97,855 thousand and net loss attributable to stockholders was $4,286 thousand versus net income of $16,903 thousand. Cash and cash equivalents declined to $11,168 thousand from $24,123 thousand at December 31, 2025, as net cash provided by operating activities fell to $2,726 thousand and the company used cash for share repurchases and settlement of a prior share repurchase liability. In May 2026, biote entered an amended and restated credit agreement providing a $125,000 thousand term loan and $50,000 thousand revolving facility maturing in 2031; term loan principal outstanding was $125,000 thousand at June 30, 2026. Total liabilities were $159,891 thousand and stockholders’ deficit was $58,192 thousand. All amounts are in thousands.

Biote Corp. reported second quarter 2026 revenue of $44.2 million, down 9.5% from $48.9 million a year earlier. Procedure revenue declined 13.9% to $30.3 million, reflecting impacts from the January 2026 voluntary recall of certain hormone pellets shipped by Asteria Health, while dietary supplements revenue grew 5.7% to $11.4 million.

Gross profit margin fell to 65.4% from 71.6%, driving an operating loss of $3.5 million versus $10.8 million of income, and a net loss of $7.4 million, or $(0.23) per diluted share, compared with $3.9 million and $0.10. Adjusted EBITDA was $5.6 million with a 12.6% margin, down from $15.2 million and 31.1%. Recall-related costs totaled $0.8 million in the quarter and $2.2 million year-to-date. As of June 30, 2026, cash was $11.2 million, total liabilities were $159.9 million, and stockholders’ deficit was $58.2 million. For 2026, Biote now guides to revenue above $175 million and Adjusted EBITDA above $25 million, expecting sequential improvement but continued year-over-year declines in procedure revenue, with dietary supplements growing at a mid to high single-digit rate.

BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Class A stock of BIOTE CORP. BlackRock reports beneficial ownership of 359,732 shares, representing 1.2% of the outstanding Class A shares. All of these shares are reported with sole voting and sole dispositive power, with no shared voting or dispositive power. The filing states that various underlying persons may have rights to dividends or sale proceeds, but no such person holds more than five percent of the total outstanding common shares.

biote Corp. amended and restated the employment agreement for Robert Peterson in connection with his role as Interim Chief Executive Officer. Under the new terms, he will receive an annual base salary of $658,800 plus eligibility for an annual incentive of up to 72.5% of base salary.

Peterson will be granted stock options to purchase a number of shares equal to 0.56% of biote’s outstanding common stock as of June 8, 2026, with an additional option grant for the same percentage if he becomes non-interim CEO. The agreement provides 12 months of salary and health insurance benefits if he is terminated without cause or resigns for specified good reasons, with enhanced payments (salary plus target bonus and accelerated vesting of certain equity awards) if such a termination occurs around a change in control.

biote Corp. interim CEO Robert Charles Peterson received a grant of stock options as part of his compensation. The award covers 206,746 options to purchase Class A common stock at an exercise price of $2.46 per share and expires on June 11, 2036. According to the vesting terms, 25% of the options will vest on June 12, 2027, with the remaining options vesting in 36 substantially equal monthly installments, subject to his continued service. Following this grant, Peterson holds 206,746 stock options directly, and the filing does not report any open-market share purchases or sales.

biote Corp. director Bret Christensen received a grant of stock options, giving him the right to buy 130,000 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.

All 130,000 option shares will vest on the earlier of June 8, 2027 or the day before biote Corp.'s 2027 Annual Meeting of Stockholders, as long as Christensen remains in continuous service through that vesting date.

biote Corp. Executive Chairman Marc D. Beer received a grant of employee stock options covering 114,157 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.

According to the vesting schedule, 25% of the options vest on June 8, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 114,157 derivative securities related to these options.

Biote Corp. announced a leadership transition while keeping its 2026 outlook intact. Bret Christensen will step down as Chief Executive Officer of BioTE effective June 8, 2026, but will remain on the Board as a Class III director and receive a new stock option for 130,000 shares as part of a separation agreement. Robert Peterson, currently Chief Financial Officer and Chief Business Officer, will become Interim Chief Executive Officer and join the Board as a Class I director, continuing to serve as principal financial officer. The Board also appointed Marc Beer as Executive Chairman, with annual base compensation of $521,200, an annual bonus opportunity of up to 85% of base pay, and an option to purchase 114,157 shares.

Under Mr. Beer’s services agreement, if his role ends without cause or he resigns for specified good reason around a change in control, he is entitled to 18 months of salary and target bonus continuation, COBRA premium payments for up to 18 months, and full vesting of certain equity awards. In its accompanying press release, Biote reaffirmed full-year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of 2026, signaling that management expects to pursue existing growth and profitability plans despite the CEO transition.

biote Corp. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class I directors, Andrew R. Heyer and Dana Jacoby, to serve until the 2029 annual meeting and until their successors are elected and qualified or earlier departure.

Heyer received 22,759,692 votes for and 3,960,800 withheld, while Jacoby received 23,020,635 votes for and 3,699,857 withheld. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 29,507,419 votes for, 67,387 against, and 7,390 abstentions.